The CooperMEX:COO 89 ROE % is -3.77% as of Apr. 2026. GuruFocus rates MEX:COO with a GF Score™ of 89/100 and a GF Value™ of MXN1,702.46 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, The Cooper ranks better than 51.44% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. The Cooper's annualized net income for the quarter that ended in Apr. 2026 was MXN-5,458 Mil. The Cooper's average Total Stockholders Equity over the quarter that ended in Apr. 2026 was MXN144,710 Mil. Therefore, The Cooper's annualized ROE % for the quarter that ended in Apr. 2026 was -3.77%.
The historical rank and industry rank for The Cooper's ROE % or its related term are showing as below:
MEX:COO'
s ROE % Range Over the Past 10 Years
Min: 2.84 Med: 5.94 Max: 54.7
Current: 2.84
During the past 13 years, The Cooper's highest ROE % was 54.70%. The lowest was 2.84%. And the median was 5.94%.
MEX:COO's ROE % is ranked better than 51.44% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs MEX:COO: 2.84
The Cooper (MEX:COO) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
The Cooper ROE % Related Terms
The Cooper ROE % Historical Data
* Premium members only.
The historical data trend for The Cooper's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's ROE % distribution charts can be found below:
* The bar in red indicates where The Cooper's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
ROE % is displayed in the 30-year financial page.
The Cooper (MEX:COO) has a ROE % of -3.77% as of Apr. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on The Cooper and its competitors. Over the past decade, The Cooper's ROE % has ranged from 2.84 to 54.70. According to the industry distribution chart, The Cooper ranks #388 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 48.6%.
Is The Cooper's ROE % too high?
The Cooper's current ROE % is -3.77%. Over the past 10 years, this metric has ranged from a low of 2.84 to a high of 54.70. Based on the distribution chart, The Cooper ranks #388 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's ROE % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #388 out of 799 companies for ROE %. This puts The Cooper in the upper half of its industry. The industry median ROE % is 2.42. Historically, The Cooper's own ROE % has ranged from 2.84 to 54.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current ROE % is -3.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (MEX:COO) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,702.46, compared to a current price of MXN1,162.20 — trading 31.7% below its estimated fair value. The current ROE % is -3.77%. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For The Cooper (MEX:COO), the current ROE % is -3.77% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (MEX:COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of MXN1,162.20 is trading 31.7% below its estimated GF Value™ of MXN1,702.46.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for MEX:COO:
ROE %: -3.77%
GF Value™: MXN1,702.46 vs. price of MXN1,162.20 (31.7% below fair value)
No single metric tells the full story. See the MEX:COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for MEX:COO
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:COO has been successfully added to your 
